Menu
02
- July 2019
- June 2019
- May 2019
- April 2019
- March 2019
- February 2019
- January 2019
- December 2018
- November 2018
- October 2018
- August 2018
- July 2018
- June 2018
- May 2018
- April 2018
- March 2018
- February 2018
- January 2018
- December 2017
- November 2017
- October 2017
- September 2017
- August 2017
- July 2017
- June 2017
- May 2017
- April 2017
- March 2017
- February 2017
- January 2017
- December 2016
- November 2016
- October 2016
- August 2016
- July 2016
- June 2016
- May 2016
- April 2016
- March 2016
- February 2016
- January 2016
- December 2015
- November 2015
- October 2015
- September 2015
- August 2015
- July 2015
- June 2015
- May 2015
- April 2015
- March 2015
- February 2015
- January 2015
- December 2014
- November 2014
- October 2014
- September 2014
- August 2014
- July 2014
- June 2014
- May 2014
- April 2014
- March 2014
- February 2014
- January 2014
- December 2013
- November 2013
- October 2013
- September 2013
- August 2013
- July 2013
- June 2013
- May 2013
- April 2013
- March 2013
- February 2013
- January 2013
- December 2012
- November 2012
- October 2012
- September 2012
- August 2012
- July 2012
- June 2012
- May 2012
- April 2012
- March 2012
- February 2012
- January 2012
- December 2011
- November 2011
- October 2011
- September 2011
- August 2011
- July 2011
- June 2011
- May 2011
- April 2011
- March 2011
- Africa
- Brexit
- Content & Brand
- Corporate Communications
- Development & Global Issues
- Digital
- Disputes
- Employee Engagement
- Events
- Financial Communications
- Geo-Political
- Health
- How Africa Tweets
- HR
- Local Government
- Philanthropy
- Portland News
- Public Affairs
- Research & Insights
- Soft Power
- Sport
- UK Politics
- Uncategorized
- US Presidential Election
Professor Hawking’s final campaign: the NHS
Professor Hawking’s persistent activism provides a blueprint for us all as we seek new ways to provide world-class care, free at the point of use, long into the future.
What happens next for UK medicines regulation?
The announcement this week that Amsterdam had been selected as the new headquarters for the European Medicines Agency (EMA), brought both excitement and concern over the future of medicine regulation policy in Europe.
Do not repeal the orphan drug tax credit
In the U.S. House, Republicans have introduced their long-awaited tax reform proposal. Their plan is to move the bill quickly through the process, pass it and get it to the Senate as soon as possible. The bill is vast and, as with any tax reform, there will be winners and losers in this battle.
Portland Health team expands globally with U.S. Partner
Alfred Jackson, a Washington-based leader in health communications, advocacy and public affairs, will lead the U.S. offer, working alongside the wider business as it continues to expand globally.
Who’s promising what for health?
Against a backdrop of chronic underfunding, longer A&E waiting times, and restrictive thresholds on new medicine uptake, health and social care has emerged as one of the dominant talking points in the election race. The three main parties have all pledged to invest billions in the NHS, yet independent health experts still suggest these promised cash injections are insufficient to plug the gap.
How will our health and pharmaceutical sectors cope with Brexit?
A demographic timebomb. “Without that safety net many may feel they have no choice but to return." That’s how Age UK described Brexit putting an end to the reciprocal healthcare agreements with our European neighbours. The charity believes that ageing expat Brits will return to these shores because they cannot access EU healthcare post-Brexit.
Testing times for pharma
Once again, the financial pressures facing the NHS reared their ugly head. NHS England (NHSE) and the National Institute for Clinical Excellence (NICE) made their recommendations in response to their joint consultation into the way drugs are evaluated and funded.
An incurable interest
Last year I joined Portland’s Health team as a Junior Account Executive, following a six month placement with Save the Children International developing health and education programmes.
Overcoming pharma’s fear of social media
The time has come for UK pharmaceutical companies to put their heads together and overcome the industry’s social media phobia. Ask anyone in pharma how well the industry uses social media and you’ll probably get a derisory snort, at best.
Infectious diseases – not gone and not forgotten
2016 has been quite the year from many perspectives. A recent editorial in The Lancet highlights some of the health-related topics that have arisen over the past 12 months and one of the main topics mentioned from this year struck a chord. I have worked in infectious diseases for longer than I care to remember, in research, medical education and also from a patient support perspective.
